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Abstract
Purpose and Method: A systematic literature review of six computerised databases was undertaken in order to
review and summarise a forward planned lung stereotactic ablative body radiotherapy (SABR) treatment
planning (TP) technique as a starting point for clinical implementation in the author’s department based on
current empirical research. The data were abstracted and content analysed to synthesise the ﬁndings based
upon a SIGN quality checklist tool.
Findings: A four-dimensional computed tomography scan should be performed upon which the internal target
volume and organs at risk (OAR) are drawn. A set-up margin of 5 mm is applied to account for inter-fraction
motion. The ﬁeld arrangement consists of a combination of 7–13 coplanar and non-coplanar beams all evenly
spaced. Beam modiﬁers are used to assist in the homogeneity of the beam, although a 20% planning target
volume dose homogeneity is acceptable. The recommended fractionations by the UK SABR Consortium are 54 Gy in
3 fractions (standard), 55–60 Gy in 5 fractions (conservative) and 50–60 Gy in 8–10 fractions (very conservative).
Conformity indices for both the target volume and OAR will be used to assess the planned distribution.
Conclusion: An overview of a clinically acceptable forward planned lung SABR TP technique based on current
literature as a starting point, with a view to inverse planning with support from the UK SABR Consortium
mentoring scheme.
Keywords: SABR; SBRT; Stereotactic ablative body radiotherapy; Stereotactic ablative body radiation
therapy; Stereotactic radiotherapy
INTRODUCTION
Stereotactic ablative body radiotherapy (SABR)
is a non-invasive technique that is based on the
principles of stereotaxis where multiple radiation
beams are precisely targeting the tumour. It
permits a dramatic reduction in irradiated volumes
facilitating hypofractionation with large daily doses
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[higher Biological Effective Dose (BED)] and a
reduced overall treatment time.1
There is now a wealth of publications on
lung SABR, mainly institutional series/phase I/II
trials. SABR is considered the gold standard
for appropriate patients where surgery is contra-
indicated. It may be considered an acceptable
standard of care for peripheral medically inoper-
able stage 1 non-small-cell lung cancer (NSCLC)
as the local control (LC) and overall survival (OS)
results are very promising ranging from 73 to
97% [local control rate (LCR)] and 62 to 81%
(OS).1–15 Table 1 provides further details of
LC and OS between external beam radiotherapy
and SABR.
The evidence presented in literature over-
whelmingly supports such a technique and
understandably explains why it may be considered
unethical not to offer an SABR service. Indeed,
many articles suggest that it is comparable with
surgical resection.13,16,17 Presently, there are only
two studies that have compared SABR and surgery
in operable patients only.13,18 Most studies have
included inoperable patients, which can increase
case selection bias into the research. The most
current study supports the above results by show-
ing the 1- and 3-year survival rates to be 94·7 and
84·7%, respectively and the LCR at 1 and 3 years
were 98 and 93%, respectively.18
Even so a direct comparison of SABR and
surgery is required. To date only the ROSEL
study19 aimed to do this. This was a phase III
randomised trial, but owing to poor recruitment
the study was terminated in September 2011.
Nevertheless, it’s treatment planning (TP) and
organs at risk (OAR) constraints have been
recommended for use by the UK SABR
Consortium.20,21
The aim of this literature review focusses
on the forward planned SABR TP technique
as this would be the starting point for any
clinical implementation in the author’s
department. The most recent UK SABR
Consortium report21 states that the majority of
centres (7 out of 14) employ volumetric-
modulated arc therapy (VMAT) delivery and 10
out of 14 use some sort of inverse planning
technique for SABR.22
RESEARCH METHODOLOGY
The primary literature sources used were
academic and medical journals, online databases,
e-journals, Encore (SHU library catalogue) and
clinical trials. The online databases used were
as follows: ScienceDirect (Elsevier), Medline,
Embase, Cochrane Library, Cinahl (EbscoHost)
and the independent resource of Google Scholar.
The secondary sources were grey literature.
Government department reports and informa-
tion from professional bodies were used.
The two databases searched were Zetoc and
OpenGrey.
Overall, 77 pieces of evidence have been
reviewed for this study.
Literature was included/excluded if they
fulﬁlled the following criteria as shown in
Table 2.
Literature search process
Advanced searches
For the advanced searches, the PICO system was
used to identify information gained through the
literature search. For each key clinical question, a
PICO table was created.
Table 1. NSCLC SABR local control rate (LCR) and overall survival (OS) rates for stage 1 tumours1–15
LCR (%) OS (%)
EBRT SABR EBRT SABR
1 year 72–855,6 65·817 79–8113,15
2 years 48–645,7 94–9610–12,14 55·717 63–7213,15,12
3 years 22–665,6,8,9 88·1–9713–15 34± 918
5 years 13·9–568,9 73 (T2)–92 (T1)16 21± 8–25·317,18 62 (1B)–72 (1 A)16
Abbreviations: NSCLC, non-small-cell lung cancer; SABR, stereotactic ablative body radiotherapy; EBRT, external beam radiotherapy.
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Advanced searching using Boolean logic
was undertaken. For each PICO column, the
‘keywords’ were entered (using OR) and the
resultant search saved. These searches were then
combined (using OR) to achieve a search string
that included all related term/words for that
column (i.e., P: Patient/Population/Problem).
Each search was date limited by reﬁning the
search by year. ‘AND’was used to combine all of
the ‘PICO’ columns.
‘AND’ meant that all the search words
appeared in the article and ‘OR’ collects similar
search terms. Phrase marks (““) were used to
ensure searching of whole terms/keywords
(i.e., stereotactic body radiotherapy).
All searches were attempted twice. The ﬁrst
was to establish how to use the database and to
familiarise the researcher to the interface. The
second being the actual search.
All searches were done using the ‘Subject
Heading’ box ticked on and ticked off and the
‘explode’ tool was also used for all searches.
The ‘major concept/focus’ tool was not used for
searching as this reduced the amount of articles
retrieved.
Keywords
Numerous searches and keywords were used
for each column. Brieﬂy, the summarised key
searched terms can be seen in Table A1.
However, the outcome column was felt to be
too broad to achieve suitable results, and thus was
reﬁned further, as seen in Table A2.
Key author searches
The following key researchers were used to
identify any further research of relevance.
The key researchers searched were as follows:
Lagerwaard F, Timmerman R, Onishi H,
Nagata Y and Hurkmans C.
Data extraction and analysis
A quantitative checklist method was used for data
extraction based upon the quality assessment/
critical appraisal tool SIGN. The data were
collected and analysed manually and data
Table 2. Methodology inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
English language literature only. This is due to possible translation errors
in the text or omission of important information
As the ﬁrst work on lung SABR by the Karonlinska Institute in Sweden
was published in 1994/95,23 the search for evidence will be limited
to articles from 1994 onwards. This will ensure that any classical
pioneering research would not be omitted carelessly. However,
information from the past 10 years will hold the most value,
thus a further time limit was set depending upon the number
of results
The primary focus of the research considers/answers the overall research
question as well as the subareas of interest
They do not help to answer the overall research question
Human studies only They are non-English language articles
Ideally randomised controlled trials quantitative in nature and relevant
to the research question. This will increase the reliability and validity
of the data reported. However, owing to the lack of randomised
trials reported by Rowell and Williams,24 non-randomised trials will
also be used
Articles in Press. These would have been subject to the peer review
process and as such should be treated as published work
Supplement Abstracts. These too have been subject to peer review
Systematic Reviews and Service Evaluation retrospective studies
Grey literature, professional websites and clinical trials relevant to the
research question as well as subareas of interest
Only studies that use 4DCT or equivalent imaging method will be reviewed
for the purpose of the treatment planning aspect and future
recommendations section of the literature review
Abbreviations: SABR, stereotactic ablative body radiotherapy; 4DCT, four-dimensional computed tomography.
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synthesis was primarily via descriptive analysis
of the extracted data.
DISCUSSION
SABR TP technique
Gross tumour volume (GTV) and clinical target
volume (CTV) delineation
The accepted standard in the majority of SABR
trials and practice is that the CTV is the GTV
with no margin for microscopic disease exten-
sion.20 In order to contour the GTV/CTV, a
four-dimensional (4D) view of the tumour is
required, with the breathing motion being the
fourth dimension.
Internal target volume (ITV) delineation
For SABR, a four-dimensional computed
tomography (4DCT) scan is preformed upon
which an ITV created to take account of the
breathing motion of the tumour within the
patient.25 This is deﬁned as a tumour volume,
which is obtained using a 4DCT scan on either a
(i) maximum intensity projection (MIP) (this
displays the ‘maximum’ extent of breathing, thus
the maximum extent of the tumours position
during the breathing cycle. It corresponds to the
greatest voxel intensity values throughout the
4DCT), (ii) maximum inspiratory and expiratory
scans or (iii) as contoured on all ten phases of a
4DCT scan.20 Thus, for SABR patients the ITV
includes the mobile GTV and CTV.
The tumour is contoured on an MIP created
from a 4DCT scan and an average intensity
projection (AIP) is created. The AIP displays the
3DCT scan with voxels equal to the arithmetic
mean of the 4DCT electron density. As the voxel
density values in a 3D AIP dataset are more
representative of the true density values that
would be present during treatment, AIPs can be
used for dose calculation.
It is important that all ITV contours are
reviewed by two consultant oncologists with an
additional review by a consultant radiologist
highly recommended and considered best prac-
tice certainly for non-standard or complex
treatments.20
PTV delineation
A set-up margin (SM) is applied to the ITV to
create the PTV for SABR treatments. This is to
account for potential set-up errors and external
patient movement. Numerous studies (Table A3)
using 4DCT or equivalent imaging modality to
delineate the ITV have used margins of
3–5 mm.8,10,19,26–30 Other studies that have used
larger margins of 5–15 mm overall have used
3D helical scanning as the imaging
modality.1,7,11,12,14,31,32 It would therefore be advi-
sable to begin with an ITV to PTV SM of 5mm.
OAR delineation
In addition to the OAR outlined as standard
(heart, total lungs and spinal cord), the con-
sortium also recommend that the major airways
are also contoured (trachea and proximal bron-
chial tree, the proximal brachial tree, the prox-
imal trachea and the proximal bronchial tree plus
a further 2 cm).20,21
When non-coplanar beams are used the whole
liver should be scanned (especially for lower lobe
lesions) and additional OAR outlined (stomach,
bowel, spleen, brachial plexus, oesophagus and
liver). In addition, skin dose should be kept to a
minimum to reduce cutaneous and subcutaneous
toxicity. This is assisted by ensuring that beam
entry points do not overlap on the skin.21
All OAR are outlined on the AIP of a 4DCT
scan.19
Dose and fractionation schedules
Various dose fractionation schedules have been
researched, ranging from a single fraction to ten
or more and with a total dose (TD) of between
24 and 72 Gy.1,7,8,10–14,17,23,31,33,34
Dose fractionation regimes supported by the
lung consortium20,21 are as provided in Table 3.
The standard dose has been informed by the
results of the RTOG 0236 trial.35 This was a
multicentre phase II study. The prescription dose
was 20 Gy/fraction over 3 fractions (60 Gy TD)
without proper tissue heterogeneity. Subsequent
analysis with heterogeneity correction showed
the actual dose to be only 54 Gy total. This dose
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was associated with acceptable treatment-related
morbidity.
The conservative dose fractionation is recom-
mended when any a part of the PTV is in contact
with the chest wall. The inter-fraction interval is
recommended to be at least 40 hours, with a
maximum interval of ideally 4 days between
treatment fractions.19 If the dose constraints
cannot be met at 55 Gy in 5 fractions, the very
conservative fractionation schedules can be used.
The conformity constraints are as per 55 Gy in
5 fractions.
It is important to mention that the doses are
prescribed depending on the algorithm used.19
Biological Effective Dose (BED) and SABR
There has been much debate and discussion on
the contribution of the BED for hypo-
fractionated SABR, particularly as the underlying
mechanisms of cell killing and the biological
dose–response relationship between observed
effects and hypofractionation is far from under-
stood.36 In fact, after a review of literature,
Partridge et al.37 suggested that owing to the high
daily dose it is inappropriate to employ this, as the
model does not accurately explain clinical out-
comes as it is based upon the radiobiology rules of
conventional fractionation, which is different to
hypofractionation radiation therapy.
Nevertheless, the BED remains the only well-
established and researched model as an estimation
of radiation effect and as such needs consideration
when deciding a dose/fractionation schedule for
SABR. The general consensus in literature is that
higher BED over a shorter period must be given
to achieve a successful LCR.38
Onishi et al.19 undertook a retrospective
evaluation of 245 patients. After a median
follow-up (FU) of 24 months, local recurrence
rate was 8·1% for a BED≥ 100 Gy compared
with 26·4% for a BED< 100 Gy (p< 0·05) and
3-year OS rate for medically operable patients
was 88·4% for BED≥ 100 Gy compared with
69·45 for a BED< 100 Gy (p< 0·05).
In two FU studies, Onishi et al.17,16 concluded
that a BED> 100 Gy is considered to be a satis-
factory SABR dose for stage 1 NSCLC, giving an
LCR better than 85%. The BED was calculated
at the isocentre and the median calculated BED
was 116 Gy (range, 100–141 Gy).17 This is
echoed by Xia et al.9
Similarly in America, Timmerman et al.1,7
concluded that 60 Gy over three fraction was
the optimum dose. This is a calculated BED
of 180 Gy. With proper tissue heterogeneity cor-
rection, the dose was 54 Gy in 3 fractions, which is
a BED of 151·2 Gy.
Field arrangement (forward planned)
In order to achieve adequate target coverage
using SABR while sparing critical structures
including the skin surface, a multiple-beam ﬁeld
arrangement with the isocentre placed at the
centre of the PTV is the conventional technique
for SABR, which can range between 7 and
13 ﬁelds.1,31,39–44
All ﬁelds are non-opposing, evenly spaced and
most of the literature supports a non-coplanar
technique,1,12–14,17,31,39–44 although it is also
possible to use coplanar beam conﬁguration
depending on the size and location of the lesion.
Han et al.28 and Nyman et al.45 both used a
combination of co-planar and non-coplanar
beams. The large limitation of non-coplanar
angles is the increase in delivery time.42 How-
ever, with the advent of ﬂatness ﬁlter-free linacs,
treatment times for SABR have been shown to be
halved.46
Beam angles should be directed so that the
spinal cord receives the lowest dose possible;
Table 3. Dose/fractionation regimes supported by the Lung Consortium20,21
Standard 54 Gy in 3 fractions (NB 60 Gy in 3 fractions is not allowed)
Conservative 55–60 Gy in 5 fractions
Very conservative 50–60 Gy in 8–10 fractions
Notes: Each fraction is given on alternative days and resting at weekends. This is a risk-adapted fractionation approach.
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Timmerman et al.1 asked for no more than
6 Gy/fraction and beam weightings manipulated
to deliver roughly equal absolute dose to the
isocentre1 and minimum beam segment area set
to 4 cm.21
Beam energy
The lower megavoltage energies such as 4–6MV
should be used13,14,17,39,40,43,44,47 owing to the
wide penumbra of high-energy beams, the small
beam apertures used in SABR and the problems
associated with build up. The plan is recommended
to be calculated on a small dose grid (no more than
2·5 cm) to ensure the accuracy of the dose volume
histogram calculations. For lung SABR treatments,
all patients should be treated with 0·5 cm MLC or
better capable linear accelerator.32
Tissue heterogeneity correction
Dose delivered to the PTV and OARs for SABR
of lung tumours are largely inﬂuenced by tissue
density corrections.47 For SABR, it is strongly
recommended that Type B algorithms should be
used.43 This is calculated based upon the electron
density matrix of the attenuated tissues rather
than equivalent path lengths. It is a more accurate
estimation of dose near tissue/air interfaces.
Assessing the clinical acceptability of a plan
PTV conformity indices (CI)
From the review of literature there were several
standard CI used to assess the clinical acceptability
of a plan. They are seen in Table 4, assuming the
standard prescription dose.
Prescription point
Owing to the highly inhomogeneous distribu-
tions accepted with SABR, target dose homo-
geneity in the PTV should be within
20%14,17,39,40 and the target reference point dose
should be deﬁned at the isocentre of the
beam.39,40
PTV dosimetric criteria
In order to critically assess the clinical accept-
ability of a plan, the conformity of the PTV
coverage will be judged as given in the tables
below, incorporating constraints used in the
ROSEL study (Table 5).19
OAR dose constraints
The OAR constraints recommended by the
Lung Consortium are also from the ROSEL trial
(Table 6).19 They are based on the highest
Table 4. PTV conformity indices
PTV coverage constraints
Ratio calculations
R100% [Vol (100%)/
Vol (PTV)]
The ratio of the 100% (54 Gy) isodose to the PTV. This is calculated by dividing the volume of
100% isodose of the dose prescription isodose with the PTV volume
It is a calculated in order to decide whether the volume is an adequate size for SABR planning.
The R100 should be a value of 1·0–1·2 for SABR treatments
For acceptable values see Table 5
R50% [Vol (50%)/
Vol (PTV)]
The ratio of the 50% isodose (27 Gy) to the PTV. This is calculated by dividing the volume of 50%
isodose of the dose prescription isodose with the PTV volume
For acceptable values see Table 5
PTV constraints
PTV V50% The percentage of the volume of the PTV that receives 50% of the prescribed dose
PTV V99% The percentage of the volume of the PTV that receives 99% of the prescribed dose. It should be
above 90% for SABR treatments
PTV V100% The percentage of the PTV that receives 100% of the prescribed dose. It should be above 95% for
SABR treatments
Max dose>2 cm The maximum dose (% of nominal prescription dose) at least 2 cm from the PTV in any direction.
A D2cm (PTV+ 2 cm) is created to determine this constraint
For acceptable values see Table 5
Max dose The max dose within the PTV should preferably not be <59·4 Gy (110%) or >75·6 Gy (140%).
A minor deviation will be scored in cases where the max dose lies between either 56·7 and
59·4 Gy or between 75·6 and 78·3 Gy
Abbreviations: PTV, planning target volume; SABR, stereotactic ablative body radiotherapy.
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dose/fractionation regimes reported in lung
SABR and therefore should be safe for lower
BED regimes used in lung SABR.20
SUMMARY
From the literature, SABR is more commonly
associated with conventional forward plan-
ning,1,7,8,10,13,14,17,35 with only a few researchers
using co-planar inverse planned treat-
ments.44,47–49 It would therefore be advisable to
start any SABR as a forward planned technique
initially and then progress to other techniques.
Table 7 provides a summary of the technique
proposed.
FUTURE DEVELOPMENTS
This review focussed on the forward planned
SABR TP technique as this would be the starting
point for any clinical implementation in the
author’s clinical department. However, presently it
would seem that VMAT sets the standard for
SABR planning and delivery. Ong et al.50 com-
pared techniques and found that VMAT achieved
a superior CI and lower V45Gy to the chest wall
(p<0·05) compared with all other techniques
and gave far quicker delivery times (of a 7·5Gy
fraction) than other techniques: 3·9 minutes
(VMAT), 11·6 minutes (conformal SABR) and
12 minutes (ﬁxed-ﬁeld intensity-modulated
radiotherapy).50 Indeed, Naviarria et al.51 found
Table 5. Dose conformity requirements for Type B models (54 Gy in 3 fractions and 55 Gy in 5 fractions and 60 Gy in 8 and 50 Gy in 10 fractions)19
Vol (100%)/Vol (PTV) Vol (50%)/Vol (PTV) Max dose>2 cm V20 (%)
Vol (PTV)
(cc) Tolerance
Minor
deviation Tolerance
Minor
deviation
Tolerance
(Gy)
Minor deviation
(Gy) Tolerance
Minor
deviation
54 Gy in 3 fractions
<20 <1·25 1·25–1·40 <12 12–14 <35·1 35·1–40·5 <5 5–8
20–40 <1·15 1·15–1·25 <9 9–11 <37·8 37·8–43·2 <6 6–10
> 40 <1·10 1·10–1·20 <6 6–8 <37·8 37·8–43·2 <10 10–15
60–90 <1·10 1·10–1·20 <5 5–7 <37·8 37·8–43·2 <10 10–15
> 90 <1·10 1·10–1·20 <4·5 4·5–6·5 <37·8 37·8–43·2 <10 10–15
55 Gy in 5 fractions (and 60 Gy in 8 and 50 Gy in 10 fractions)
<20 <1·25 1·25–1·40 <12 12–14 <35·8 35·8–41·3 <5 5–8
20–40 <1·15 1·15–1·25 <9 9–11 <38·5 38·5–44·0 <6 6–10
> 40 <1·10 1·10–1·20 <6 6–8 <38·5 38·5–44·0 <10 10–15
60–90 <1·10 1·10–1·20 <5 5–7 <38·5 38·5–44·0 <10 10–15
> 90 <1·10 1·10–1·20 <4·5 4·5–6·5 <38·5 38·5–44·0 <10 10–15
Abbreviations: Vol (100%)/Vol (PTV), ratio of prescription isodose (e.g., 54 or 55 Gy) volume to the PTV; Vol (50%)/Vol (PTV), ratio of 50%
prescription isodose (27 or 27·5 Gy) volume to the PTV; Max dose>2 cm, maximum dose (% of nominal prescription dose) at least 2 cm from the PTV
in any direction; V20, percentage of total lung volume—GTV receiving >20 Gy; PTV, planning target volume; GTP, gross tumour volume.
Table 6. OAR dose constraints Administrator19
3 fraction regime 5 fraction regime 10 fraction regime
Organ Volume Tolerance
Minor
deviation Tolerance
Minor
deviation Tolerance
Minor
deviation
Spinal cord Any point 18 Gy >18–22 Gy 25 Gy >25–28 Gy 25 Gy >25–28 Gy
Oesophagus 1 cc3 24 Gy >24–27 Gy 27 Gy >27–28·5 Gy 27 Gy >27–28·5 Gy
Ipsilateral brachial plexus 1 cc3 24 Gy >24–26 Gy 27 Gy >27–29 Gy 27 Gy >27–29 Gy
Heart 1 cc3 24 Gy >24–26 Gy 27 Gy >27–29 Gy 50 Gy >50–60 Gy
Trachea/ipsilateral
bronchus
1 cc3 30 Gy >30–32 Gy 32 Gy >32–35 Gy 32 Gy >32–35 Gy
Lungs—GTV V20,
V12·5
<10%,
<15%
N/A <10%,
<15%
N/A <10%,
<15%
N/A
Abbreviations: OAR, organs at risk; GTP, gross tumour volume.
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Table 7. SABR pre-treatment summary
Patient selection
Strict eligibility
criteria
Two clinical oncologists and CT
radiographers
Patient must ﬁt the eligibility criteria as recommended by the consortium
CT scanning
Immobilisation CT therapy radiographers A ‘wing board’ with an evacuated bag and foot rest and abdominal compression where indicated
Scanning method CT therapy radiographers 4DCT with contrast
Scanning limit The scan will extend from the upper cervical spine to the lower edge of the liver—this should ensure
inclusion of
all OAR Transverse slice thickness should be 3 mm minimum
Volume deﬁnition
ITV Two clinical oncologists and radiologist Outlined on the MIP of the 4DCT scan using diagnostic imaging information including PET-CT
ITV geographical position must ﬁt the inclusion criteria by the consortium
SM (PTV) Physics and treatment planning 0·5 cm margin added isotropically to ITV
OAR deﬁnition
OAR delineation Two clinical oncologists and radiologist Outlined on the AIP
Spinal cord, liver, heart, trachea, oesophagus, brachial plexus, proximal bronchial tree, the proximal
brachial tree,
the proximal trachea and the proximal bronchial tree plus 2 cm
The consortium proposes that that the spinal cord alone is contoured to the bony limits of the vertebra
However, a planning risk volume of 0·5 cm will be applied isotropically to the actual spinal cord as this
is the clinical practice at the author’s clinical department. This is a more generous margin than that
proposed by the consortium.
Its use will be assessed during the intended planning studies
Treatment planning
Algorithm Physics/treatment planning A Type B (AAA) algorithm will be used on an Varian Eclipse treatment planning system
Grid size 2·5 mm
Energy 6 MV
Number of ﬁelds and
arrangement
7–13 non-opposing ﬁelds. Directed to reduce OAR doses
Combination of co-planar and non-coplanar
Beam modiﬁers EDW and static MLCs
Dose prescription
and fractionation
Standard; 54 Gy in 3 fractions (NB 60 Gy in 3 fractions is not allowed)
Conservative; 55–60 Gy in 5 fractions
Very conservative; 50–60 Gy in 8–10 fractions
Conformity indices Refer to Table 4
Volume constraints Refer to ROSEL constraints (Table 5)
OAR constraints Refer to ROSEL constraints (Table 6)
Abbreviations: SABR, stereotactic ablative body radiotherapy; 4DCT, four-dimensional computed tomography; OAR, organs at risk; ITV, internal target volume; MIP, maximum intensity projection;
PET-CT, positron emission tomography computed tomography; SM, set-up margin; PTV, planning target volume; AIP, average intensity projection.
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that themedian beam on timewas reduced by 75%
for VMAT plans and Boda-Heggemann et al.46
found by using ﬂatness ﬁlter-free linacs during one
breath hold, treatment time was reduced by half.
These results are being echoed throughout
the most current literature; VMAT gives
improved highly conformal dose distributions
while achieving accurate dosimetric delivery and
improved treatment times.44,47–49
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Table A1. Keyword/term searches
P I C O
Problem/Patient/Population Intervention/Indicator Comparison Outcome
‘Non-small cell lung cancer’ (indexed term) ‘Stereotactic Body Radiotherapy’ (indexed term) ‘Local Control’ (keyword)
T1a SBRT ‘Prognosis’ (indexed term)
T1b ‘Stereotactic Ablative Body Radiotherapy’ ‘Cancer Prognosis’ (indexed term)
‘Early Stage Lung Cancer’ SABR ‘Cancer Survival’ (indexed term)
‘Lung Cancer’ ‘Stereotactic Body Radiation Therapy’ ‘Survival Rate’ (indexed term)
‘Stereotactic Ablative Body Radiation Therapy’ ‘Overall Survival’ (indexed term)
‘Survival’ (indexed term)
‘Treatment Outcome’ (indexed term)
‘Treatment Planning’
‘Treatment Planning Technique’
‘Dosimetric Analysis’
‘Volumetric Analysis’
‘Radiotherapy Treatment Planning’
‘Radiation Treatment Planning’
‘RT Treatment Planning’
‘Dosimetry’ (indexed term)
‘Treatment Planning’ (indexed term)
Abbreviations: SBRT, stereotactic body radiation therapy; SABR, stereotactic ablative body radiotherapy.
APPENDIX
Table A2. Keyword/term searches
O
Outcome
‘Target Volumes’ ‘Organs at
Risk’
‘Conformity Indices’ ‘Forward Planned’ OR ‘Forward Planning’ ‘Field Arrangement’ ‘Dose Prescription’
‘Planning Target Volume’ ‘Dose Constraints’ ‘Conformity Index’ ‘Inverse Planned’ OR ‘Inverse
Planning’
‘Algorithm’ (indexed term)
‘Hypofractionated Radiotherapy’
‘Clinical Target Volumes’ Delineation ‘Dose Conformity’ ‘Volumetric Modulated Arc Therapy’ ‘Photon Beam Energy’ ‘Prescription’ (indexed term)
‘Gross Tumour Volumes’ ‘Tumour Volume’
(indexed term)
Outlining ‘Dose Constraints’ ‘Intensity Modulated Radiotherapy’
(indexed term)
‘Treatment Planning’
(indexed term)
‘Radiotherapy’ (indexed term)
‘Tumour Volume’ (indexed term) ‘Dosimetry’ (indexed term) ‘Conformal Radiotherapy’ ‘Radiotherapy’ (indexed
term)
‘Radiation Dose’ (indexed term)
Delineation ‘Dose Volume Histogram’ ‘Rapid Arc’ ‘Dosimetry’ (indexed term) ‘Radiation Dose Fractionation’
(indexed term)
Outlining Histogram (indexed term) ‘Radiotherapy’ (indexed term)
‘Internal Target Volumes’ ‘Treatment Planning’
(indexed term)
‘Treatment Planning’ (indexed term)
‘Treatment Planning’ (indexed term) ‘Radiation Dose’ (indexed term)
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Table A3. Summary of volumes and margins applied in literature
Study Patient number Imaging method GTV CTV ITV PTV/SM Total margin (mm)
4DCT or equivalent
de Koste et al.52 7 3DCT (equivalent of 4DCT) (three
rapid CT scans and
three slow scans
co-registered)
Yes 5 mm No 5 mm 10
Jin et al.27 Phantom Study 3DCT (equivalent of 4DCT) (one gated
CTs at end and
start of inspiration and expiration
and one mid-phase)
As ITV As ITV Yes 3 mm (circumferentially),
5 mm superior/inferior for
residual motion
3–5
Underberg et al.26 10 4DCT As ITV As ITV Yes 3 mm 3
Gukenburger
et al.30
24 3DCT (equivalent of 4DCT) (three
dynamic CT studies in deep
inspiration, deep expiration and CT
scans) (15 seconds, one image
per second)
As ITV As ITV Yes 5 mm circumferentially 5
Lagerwaard
et al.8,10
197–206 4DCT Yes No Yes 3 mm circumferentially 3
Hurkmans et al.19 N/A 4DCT Yes No Yes (deﬁned as the
GTV on the MIP)
3–5 mm circumferentially 3–5
Han et al.28 24 4DCT Yes No Yes (deﬁned as the
GTV on the MIP)
5 mm circumferentially 5 (circumferentially)
Li et al.29 133 4DCT Yes No Yes (deﬁned as the
GTV on the MIP)
5 mm circumferentially 5
3DCT
Dvorak et al.32 10 Helical 3DCT+D3 Not stated Yes No 7 mm anterior/posterior, left/
right and 10 mm superior/
inferior
7–10
Timmerman et al.11
Phase I; McGarry
et al.31 Phase I;
Fakiris et al.12
Phase II;
Timmerman et al.1
Phase II;
Timmerman et al.7
Phase II (RTOG)
47–70 Helical 3DCT Yes As GTV No 5 mm anterior/posterior, left/
right and 10 mm superior/
inferior
5–10
Onishi et al.13 87 Helical 3DCT Yes 0–5 mm 2–5 mm (according to
individual
respiratory motion)
5 mm 7–15
Abbreviations: GTV, gross tumour volume; CTV, clinical target volume; ITV, internal target volume; PTV, planning target volume; SM, set-up margin; 4DCT, four-dimensional computed tomography;
MIP, maximum intensity projection.
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